drugset
drugset / Trial / NCT06190145

Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia

NCT06190145 ↗

Phase 2 Unknown 40 enrolled Peking University People's Hospital
NaSingle-groupOpen-labelTreatment

Summary

Single-arm, open-label, single-center study to evaluate the efficacy and safety of teriflunomide for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).

Timeline

Start
2023-12-05
Primary completion
2024-10-15
Completion
2025-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriflunomide Small molecule 7 mg Oral

Indications

autoimmune thrombocytopenia